Endometrial Cancer - Pipeline Review, H2 2017

Date: November 28, 2017
Pages: 647
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: EDB45DD5E76EN
Leaflet:

Download PDF Leaflet

Endometrial Cancer - Pipeline Review, H2 2017
Endometrial Cancer - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Endometrial Cancer - Pipeline Review, H2 2017, provides an overview of the Endometrial Cancer (Oncology) pipeline landscape.

Endometrial cancer is cancer that starts in the endometrium, the lining of the uterus (womb). Endometrial cancer is the most common type of uterine cancer. Although the exact cause of endometrial cancer is unknown, increased levels of estrogen appear to play a role. Estrogen helps stimulate the buildup of the lining of the uterus. Symptoms of endometrial cancer include abnormal bleeding from the vagina, including bleeding between periods or spotting/bleeding after menopause, extremely long, heavy or frequent episodes of vaginal bleeding after age 40, lower abdominal pain or pelvic cramping and thin white or clear vaginal discharge after menopause.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Endometrial Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Endometrial Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Endometrial Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Endometrial Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 39, 41, 1 and 16 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 3 and 1 molecules, respectively.

Endometrial Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Endometrial Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Endometrial Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Endometrial Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Endometrial Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Endometrial Cancer (Oncology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Endometrial Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Endometrial Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Endometrial Cancer - Overview
Endometrial Cancer - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Endometrial Cancer - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Endometrial Cancer - Companies Involved in Therapeutics Development
AbbVie Inc
Ability Pharmaceuticals SL
Advenchen Laboratories LLC
Aeterna Zentaris Inc
ArQule Inc
Arrien Pharmaceuticals LLC
AstraZeneca Plc
AVEO Pharmaceuticals Inc
Bayer AG
BeiGene Ltd
BioNTech AG
Biscayne Pharmaceuticals Inc
Boehringer Ingelheim GmbH
CBT Pharmaceuticals Inc
Critical Outcome Technologies Inc
CytomX Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Co
Esperance Pharmaceuticals Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Galena Biopharma Inc
GamaMabs Pharma SA
Genmab A/S
GlaxoSmithKline Plc
Glycotope GmbH
Gradalis Inc
Horizon Pharma Plc
Immunocore Ltd
ImmunoGen Inc
Immunomedics Inc
Incyte Corp
Innate Pharma SA
Innovation Pharmaceuticals Inc
Karyopharm Therapeutics Inc
MedImmune LLC
Merck & Co Inc
Merck KGaA
Merrimack Pharmaceuticals Inc
Mersana Therapeutics Inc
Merus NV
Millennium Pharmaceuticals Inc
Moderna Therapeutics Inc
Novartis AG
OncoResponse Inc
Ono Pharmaceutical Co Ltd
Pfizer Inc
Pharma Mar SA
Pivot Pharmaceuticals Inc
PTC Therapeutics Inc
Puma Biotechnology Inc
Sanofi
Shenogen Pharma Group Ltd
Sigma-Tau SpA
Sutro Biopharma Inc
Syndax Pharmaceuticals Inc
Synthon Holdings BV
Taiho Pharmaceutical Co Ltd
Tesaro Inc
Vyriad Inc
Endometrial Cancer - Drug Profiles
212 Pb-TCMC-Trastuzumab - Drug Profile
2X-121 - Drug Profile
2X-131 - Drug Profile
ABTL-0812 - Drug Profile
AEZS-138 - Drug Profile
AL-3818 - Drug Profile
anetumab ravtansine - Drug Profile
ARN-3261 - Drug Profile
atezolizumab - Drug Profile
AV-203 - Drug Profile
avelumab - Drug Profile
AZD-5363 - Drug Profile
BAY-1082439 - Drug Profile
BAY-1895344 - Drug Profile
BGB-283 - Drug Profile
BGBA-317 - Drug Profile
BIS-1602 - Drug Profile
buparlisib hydrochloride - Drug Profile
cabozantinib s-malate - Drug Profile
CBT-501 - Drug Profile
Cellular Immunotherapy for Oncology - Drug Profile
Cellular Immunotherapy for Ovarian and Endometrial Cancer - Drug Profile
Cellular Immunotherapy to Taregt HER-2 for Oncology - Drug Profile
COTI-2 - Drug Profile
cridanimod - Drug Profile
CX-2009 - Drug Profile
durvalumab - Drug Profile
durvalumab + tremelimumab - Drug Profile
emactuzumab - Drug Profile
endoxifen hydrochloride - Drug Profile
entinostat - Drug Profile
EP-100 - Drug Profile
EP-200 - Drug Profile
epacadostat - Drug Profile
everolimus - Drug Profile
FAZ-053 - Drug Profile
GALE-301 - Drug Profile
gedatolisib - Drug Profile
gemogenovatucel-T - Drug Profile
GM-102 - Drug Profile
GSK-2256098 - Drug Profile
GSK-2636771 - Drug Profile
HO-3867 - Drug Profile
HuMax-AXL-ADC - Drug Profile
IMCD-104C - Drug Profile
INCAGN-1876 - Drug Profile
INCAGN-1949 - Drug Profile
INCB-50465 - Drug Profile
INCB-54828 - Drug Profile
interferon gamma-1b - Drug Profile
itacitinib adipate - Drug Profile
Kevetrin - Drug Profile
lenvatinib mesylate - Drug Profile
lurbinectedin - Drug Profile
LY-3023414 - Drug Profile
M-9831 - Drug Profile
MCLA-128 - Drug Profile
MCS-110 - Drug Profile
miransertib - Drug Profile
mirvetuximab soravtansine - Drug Profile
MK-2206 - Drug Profile
MM-161 - Drug Profile
MM-310 - Drug Profile
monalizumab - Drug Profile
Monoclonal Antibody to Inhibit L1CAM for Ovarian and Endometrial Cancer - Drug Profile
mRNA-4157 - Drug Profile
namitecan - Drug Profile
neratinib - Drug Profile
nintedanib - Drug Profile
niraparib - Drug Profile
nivolumab - Drug Profile
ONC-201 - Drug Profile
ONCO-101 - Drug Profile
Oncolytic Virus to Activate IFNb and SLC5A5 for Endometrial Cancer - Drug Profile
Oncolytic Virus to Activate IFNB and SLC5A5 for Hematological Malignancies - Drug Profile
Oncolytic Virus to Target CD46 and SLC5A5 for Oncology - Drug Profile
ONCR-201 - Drug Profile
palbociclib - Drug Profile
PankoMab-GEX - Drug Profile
PDR-001 - Drug Profile
pembrolizumab - Drug Profile
Peptides to Antagonize GnRH II Receptor for Oncology - Drug Profile
pimasertib hydrochloride + voxtalisib - Drug Profile
PM-184 - Drug Profile
PRI-724 - Drug Profile
PTC-596 - Drug Profile
PVT-005 - Drug Profile
sacituzumab - Drug Profile
sapanisertib - Drug Profile
SAR-408701 - Drug Profile
SC-004 - Drug Profile
selinexor - Drug Profile
sirolimus albumin-bound - Drug Profile
Small Molecules to Inhibit Skp2 for Endometrial Cancer and Melanoma - Drug Profile
SNG-1153 - Drug Profile
SP-2509 - Drug Profile
Stem Cell Therapy to Activate SLC5A5 for Oncology - Drug Profile
STRO-002 - Drug Profile
TAS-117 - Drug Profile
tisotumab vedotin - Drug Profile
trametinib dimethyl sulfoxide + uprosertib - Drug Profile
trastuzumab duocarmazine - Drug Profile
TSR-042 - Drug Profile
vistusertib - Drug Profile
XMT-1536 - Drug Profile
Endometrial Cancer - Dormant Projects
Endometrial Cancer - Discontinued Products
Endometrial Cancer - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Endometrial Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Endometrial Cancer - Pipeline by AbbVie Inc, H2 2017
Endometrial Cancer - Pipeline by Ability Pharmaceuticals SL, H2 2017
Endometrial Cancer - Pipeline by Advenchen Laboratories LLC, H2 2017
Endometrial Cancer - Pipeline by Aeterna Zentaris Inc, H2 2017
Endometrial Cancer - Pipeline by ArQule Inc, H2 2017
Endometrial Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2 2017
Endometrial Cancer - Pipeline by AstraZeneca Plc, H2 2017
Endometrial Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2017
Endometrial Cancer - Pipeline by Bayer AG, H2 2017
Endometrial Cancer - Pipeline by BeiGene Ltd, H2 2017
Endometrial Cancer - Pipeline by BioNTech AG, H2 2017
Endometrial Cancer - Pipeline by Biscayne Pharmaceuticals Inc, H2 2017
Endometrial Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Endometrial Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2017
Endometrial Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2017
Endometrial Cancer - Pipeline by CytomX Therapeutics Inc, H2 2017
Endometrial Cancer - Pipeline by Eisai Co Ltd, H2 2017
Endometrial Cancer - Pipeline by Eli Lilly and Co, H2 2017
Endometrial Cancer - Pipeline by Esperance Pharmaceuticals Inc, H2 2017
Endometrial Cancer - Pipeline by Exelixis Inc, H2 2017
Endometrial Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Endometrial Cancer - Pipeline by Galena Biopharma Inc, H2 2017
Endometrial Cancer - Pipeline by GamaMabs Pharma SA, H2 2017
Endometrial Cancer - Pipeline by Genmab A/S, H2 2017
Endometrial Cancer - Pipeline by GlaxoSmithKline Plc, H2 2017
Endometrial Cancer - Pipeline by Glycotope GmbH, H2 2017
Endometrial Cancer - Pipeline by Gradalis Inc, H2 2017
Endometrial Cancer - Pipeline by Horizon Pharma Plc, H2 2017
Endometrial Cancer - Pipeline by Immunocore Ltd, H2 2017
Endometrial Cancer - Pipeline by ImmunoGen Inc, H2 2017
Endometrial Cancer - Pipeline by Immunomedics Inc, H2 2017
Endometrial Cancer - Pipeline by Incyte Corp, H2 2017
Endometrial Cancer - Pipeline by Innate Pharma SA, H2 2017
Endometrial Cancer - Pipeline by Innovation Pharmaceuticals Inc, H2 2017
Endometrial Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2017
Endometrial Cancer - Pipeline by MedImmune LLC, H2 2017
Endometrial Cancer - Pipeline by Merck & Co Inc, H2 2017
Endometrial Cancer - Pipeline by Merck KGaA, H2 2017
Endometrial Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H2 2017
Endometrial Cancer - Pipeline by Mersana Therapeutics Inc, H2 2017
Endometrial Cancer - Pipeline by Merus NV, H2 2017
Endometrial Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
Endometrial Cancer - Pipeline by Moderna Therapeutics Inc, H2 2017
Endometrial Cancer - Pipeline by Novartis AG, H2 2017
Endometrial Cancer - Pipeline by OncoResponse Inc, H2 2017
Endometrial Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
Endometrial Cancer - Pipeline by Pfizer Inc, H2 2017
Endometrial Cancer - Pipeline by Pharma Mar SA, H2 2017
Endometrial Cancer - Pipeline by Pivot Pharmaceuticals Inc, H2 2017
Endometrial Cancer - Pipeline by PTC Therapeutics Inc, H2 2017
Endometrial Cancer - Pipeline by Puma Biotechnology Inc, H2 2017
Endometrial Cancer - Pipeline by Sanofi, H2 2017
Endometrial Cancer - Pipeline by Shenogen Pharma Group Ltd, H2 2017
Endometrial Cancer - Pipeline by Sigma-Tau SpA, H2 2017
Endometrial Cancer - Pipeline by Sutro Biopharma Inc, H2 2017
Endometrial Cancer - Pipeline by Syndax Pharmaceuticals Inc, H2 2017
Endometrial Cancer - Pipeline by Synthon Holdings BV, H2 2017
Endometrial Cancer - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2017
Endometrial Cancer - Pipeline by Tesaro Inc, H2 2017
Endometrial Cancer - Pipeline by Vyriad Inc, H2 2017
Endometrial Cancer - Dormant Projects, H2 2017
Endometrial Cancer - Dormant Projects, H2 2017 (Contd.1), H2 2017
Endometrial Cancer - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Endometrial Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

AbbVie Inc
Ability Pharmaceuticals SL
Advenchen Laboratories LLC
Aeterna Zentaris Inc
ArQule Inc
Arrien Pharmaceuticals LLC
AstraZeneca Plc
AVEO Pharmaceuticals Inc
Bayer AG
BeiGene Ltd
BioNTech AG
Biscayne Pharmaceuticals Inc
Boehringer Ingelheim GmbH
CBT Pharmaceuticals Inc
Critical Outcome Technologies Inc
CytomX Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Co
Esperance Pharmaceuticals Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Galena Biopharma Inc
GamaMabs Pharma SA
Genmab A/S
GlaxoSmithKline Plc
Glycotope GmbH
Gradalis Inc
Horizon Pharma Plc
Immunocore Ltd
ImmunoGen Inc
Immunomedics Inc
Incyte Corp
Innate Pharma SA
Innovation Pharmaceuticals Inc
Karyopharm Therapeutics Inc
MedImmune LLC
Merck & Co Inc
Merck KGaA
Merrimack Pharmaceuticals Inc
Mersana Therapeutics Inc
Merus NV
Millennium Pharmaceuticals Inc
Moderna Therapeutics Inc
Novartis AG
OncoResponse Inc
Ono Pharmaceutical Co Ltd
Pfizer Inc
Pharma Mar SA
Pivot Pharmaceuticals Inc
PTC Therapeutics Inc
Puma Biotechnology Inc
Sanofi
Shenogen Pharma Group Ltd
Sigma-Tau SpA
Sutro Biopharma Inc
Syndax Pharmaceuticals Inc
Synthon Holdings BV
Taiho Pharmaceutical Co Ltd
Tesaro Inc
Vyriad Inc
Skip to top


Colon Cancer - Pipeline Review, H2 2016 US$ 2,500.00 Dec, 2016 · 722 pages
Kidney Cancer - Pipeline Review, H1 2015 US$ 2,000.00 Jun, 2015 · 847 pages
Peritoneal Cancer - Pipeline Review, H2 2017 US$ 2,000.00 Oct, 2017 · 876 pages
Rectal Cancer - Pipeline Review, H2 2017 US$ 2,000.00 Aug, 2017 · 128 pages
Ureter Cancer - Pipeline Review, H2 2017 US$ 2,000.00 Oct, 2017 · 144 pages

Ask Your Question

Endometrial Cancer - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: